Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock Has Consensus Price Target of $27.08 According to Analysts

Trevi Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly positive: 13 firms give Trevi Therapeutics a consensus “Moderate Buy” rating, with 11 Buy and one Strong Buy recommendation; the average 12-month price target is $27.08.
  • TRVI opened at $14.33, well below the consensus target. Its latest quarterly loss of $0.11 per share matched analysts’ expectations.
  • Institutional investors own 95.76% of the stock, while a company director sold 39,473 shares, reducing his direct stake by 86.14%.
  • MarketBeat previews top five stocks to own in December.

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $27.08.

A number of research firms have issued reports on TRVI. Weiss Ratings reissued a "sell (d-)" rating on shares of Trevi Therapeutics in a research report on Thursday, October 15th. JonesTrading lifted their price objective on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the company a "buy" rating in a report on Friday, August 14th. Wall Street Zen downgraded shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. Cantor Fitzgerald upped their price objective on shares of Trevi Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Finally, HC Wainwright increased their target price on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Monday, July 20th.

Check Out Our Latest Report on TRVI

Trevi Therapeutics Stock Performance

TRVI stock opened at $14.33 on Friday. Trevi Therapeutics has a one year low of $9.82 and a one year high of $20.22. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of -42.15 and a beta of 1.15. The firm has a 50-day simple moving average of $14.27 and a two-hundred day simple moving average of $14.39.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). As a group, equities analysts predict that Trevi Therapeutics will post -0.48 earnings per share for the current fiscal year.

Insider Activity at Trevi Therapeutics

In other news, Director Michael Heffernan sold 39,473 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total value of $595,647.57. Following the completion of the sale, the director directly owned 6,351 shares in the company, valued at $95,836.59. This represents a 86.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 15.39% of the company's stock.

Institutional Trading of Trevi Therapeutics

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Trevi Therapeutics during the 2nd quarter worth about $208,041,000. Artia Global Partners LP purchased a new stake in shares of Trevi Therapeutics in the 2nd quarter valued at approximately $41,232,000. First Light Asset Management LLC purchased a new position in Trevi Therapeutics in the second quarter valued at $39,113,000. Assenagon Asset Management S.A. raised its position in shares of Trevi Therapeutics by 131.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,527,035 shares of the company's stock worth $50,507,000 after acquiring an additional 2,001,721 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in shares of Trevi Therapeutics during the 2nd quarter worth approximately $28,588,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

About Trevi Therapeutics

(Get Free Report)

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company's lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.

Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder.

Further Reading

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Trevi Therapeutics Right Now?

Before you consider Trevi Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trevi Therapeutics wasn't on the list.

While Trevi Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines